CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The startup's in-house projects include GM-1020, a small-molecule NMDA receptor channel blocker – the mechanism of action for ketamine – which is in phase 2a clinical development for major ...

This study presents a valuable finding on the alterations in the autophagic-lysosomal pathway in a Huntington's disease model. The evidence supporting the claims of the authors is solid. However, the ...

Novel therapies, particularly those targeting the glutamatergic system, have garnered significant attention. Intravenous ketamine and intranasal S-ketamine are at the forefront of these developments.

Jan. 24, 2025 — The vestibular system is a network of organs in the inner ears that detects the motions and position of the head. The brain uses this information, ... Progress and Challenges in ...

Jan. 13, 2025 — A new study found no changes in opioid outcomes among the general population with the states' passage of medical and recreational marijuana laws. However, the findings also show ...